Which Cancer Screenings Actually Matter at Your Age

This is a map, not a mandate. Below are the major screenings the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) recommend, organized by what changes the decision: your age, your sex, and your risk. Where the two bodies disagree, that is named plainly, because knowing they differ is what lets you have the real conversation with your clinician.

The tests that changed while you weren't looking

Two of the most common screenings moved in recent years, and the advice you remember may be out of date.

Colorectal cancer is the clearest change. The USPSTF now recommends screening starting at age 45 for average-risk adults, down from the old start age of 50, and continues screening through age 75. It rates the benefit for ages 45 to 49 as moderate and the benefit for ages 50 to 75 as substantial. For adults 76 to 85, screening becomes an individual decision based on prior screening and health. The American Cancer Society agrees: it also recommends regular screening begin at 45. The test can be a colonoscopy or a stool-based test, and the choice affects how often you repeat it.

Breast cancer is where the two big bodies part ways, so it is worth knowing both. The USPSTF, in its 2024 update, recommends a screening mammogram every two years for women aged 40 to 74. The ACS recommends something different: women 40 to 44 have the option to start yearly mammograms, women 45 to 54 should screen every year, and women 55 and older can move to every other year or continue yearly. Same disease, two defensible schedules. Neither is wrong, and your density and family history can push the decision. What matters is that "when should I start" has more than one right answer, and your own risk is the tiebreaker.

Cervical screening: fewer tests, better tests

Cervical cancer screening has moved toward doing less, but doing it smarter, because nearly all cervical cancer is driven by persistent high-risk HPV.

Per the USPSTF, screening begins at age 21. From 21 to 29, the recommendation is cervical cytology (a Pap test) alone every three years. From 30 to 65, the preferred approach is primary high-risk HPV testing every five years, with two accepted alternatives: a Pap test alone every three years, or HPV testing combined with cytology every five years. Screening generally stops after 65 for those with an adequate history of prior normal results. Under 21, screening is not recommended even if someone is sexually active, because most HPV in that age group clears on its own. The theme is a longer interval with a better test, not more frequent testing.

Lung screening is for a specific group, and it misses others

Lung cancer screening is powerful, but only for people who fit a narrow eligibility window, and plenty of people who worry about lung cancer do not qualify while some who do qualify never get offered it.

The USPSTF recommends annual low-dose CT for adults aged 50 to 80 who have a 20 pack-year smoking history and either smoke now or quit within the past 15 years. Screening stops once someone has not smoked for 15 years, or develops a condition that limits life expectancy or the ability to undergo curative surgery. A pack-year is one pack a day for a year, so a 20 pack-year history could be one pack a day for 20 years or two packs a day for 10. If you meet the criteria, this is one of the highest-yield screens available. If you never smoked, a low-dose CT is not a routine screen for you, and a symptom like a persistent cough gets worked up on its own path. The details of who qualifies, and who slips through, are covered in who qualifies for a lung cancer CT screen.

Prostate screening is a conversation, not a default

Prostate screening is the one where the guideline is explicitly a discussion rather than an order.

For men aged 55 to 69, the USPSTF says the decision to have periodic PSA-based screening should be individual, made after a conversation about the benefits and harms. It is a grade C recommendation, meaning modest benefit that depends on personal values. Screening can prevent a small number of prostate cancer deaths, but it also carries real harms: false positives, overdiagnosis of cancers that would never have caused trouble, and complications from treatment. For men 70 and older, the USPSTF recommends against routine PSA screening. Family history and ancestry can shift when the conversation should start. Because a PSA number rarely means what people fear it means, understanding how to read PSA and the screening decision is what turns an anxious result into an informed choice.

Matching the test to you, instead of over- or under-screening

The point of a screening map is not to do every test. It is to do the right ones on time. Over-screening drives false alarms, unnecessary biopsies, and overtreatment of things that would never have hurt you. Under-screening lets a treatable cancer grow past the window where screening helps. Both failures come from the same root: a generic schedule that ignores your age, sex, and risk. Personal and family history, prior results, and genetics (a BRCA or Lynch finding, for example) can move a start date years earlier or change the interval entirely. The right plan is the one built around your specific numbers and updated as they change.

How Healz keeps your screening schedule straight

A screening plan is only useful if something holds it over time and updates it as your results come in. Healz does that in one chat, not ten apps. It does three things by design.

First, Healz is equipped with memory. It remembers every result you upload, along with your age, sex, and family history, and connects them across years, so it can tell the lung CT you cleared two years ago apart from the colonoscopy that is now due. Second, Healz is equipped with root-cause technology. It does not stop at a normal-looking report. It cross-checks your case against 1M+ rare cases and drills past the reassuring line to the risk others skip. Third, Healz has Frontier AI, the strongest AI working your case, reading your labs, imaging, and history together instead of one document at a time.

That is the all-in-one: Frontier AI, root-cause technology, and memory in a single place. So using an AI for cancer risk, or getting an AI second opinion on a report, no longer means juggling separate tools, and a cancer AI that already knows your history beats one you re-explain yourself to every visit. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.